CAMBRIDGE, Mass., June 5, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced its participation in the following upcoming investor conferences:

• Goldman Sachs 36^th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 10, 2015 at 4:00 p.m. PT (7:00 p.m. ET).
• JMP Securities Life Sciences Conferencein New York, NY on Tuesday, June 23, 2015 at 11:00 a.m. ET.

Live webcasts of both events will be available by visiting the Investors section of the Blueprint Medicines website at www.blueprintmedicines.com. Archived replays of the webcast will be available on the Company's website for 30 days after the conference.

About Blueprint Medicines
Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-june-300094637.html

SOURCE Blueprint Medicines

Investor Relations: Beth DelGiacco, Stern Investor Relations, Inc., 212-362-1200, beth@sternir.com; Media: Beth Keshishian, inVentiv Health PR, 212-229-8417, beth.keshishian@inventivhealth.com